abstract |
The present invention relates to alpha-synuclein (a-synuclein, A-synuclein, alpha-synuclein, A-syn, alpha-syn, aSyn, a-syn) aggregate-related diseases, disorders and abnormalities including but not limited to: Lewy bodies and/or Lewy neurites such as Parkinson's disease, multiple system atrophy, Lewy Lewy body dementia (LBD; dementia with Lewy bodies (DLB) ("pure" dementia with Lewy bodies), Parkinson's disease dementia (PDD)) or diffuse Lewy body disease. The present invention relates to alpha-synuclein binding molecules, in particular alpha-synuclein antibodies or antigen-binding fragments or derivatives thereof, and uses thereof. Molecules of the invention can also be used to determine a predisposition to such a condition, disease or abnormality, to monitor residual conditions, disease or abnormality, or to predict the response of a patient with such a condition, disease or abnormality to treatment with a drug responsiveness to treatment. |